| Structure-guided design of IACS-9571, a selective high-affinity dual TRIM24-BRPF1 bromodomain inhibitor WS Palmer, G Poncet-Montange, G Liu, A Petrocchi, N Reyna, ... Journal of medicinal chemistry 59 (4), 1440-1454, 2016 | 155 | 2016 |
| NAD kinases use substrate-assisted catalysis for specific recognition of NAD G Poncet-Montange, L Assairi, S Arold, S Pochet, G Labesse Journal of biological chemistry 282 (47), 33925-33934, 2007 | 52 | 2007 |
| The human orphan nuclear receptor tailless (TLX, NR2E1) is druggable C Benod, R Villagomez, CS Filgueira, PK Hwang, PG Leonard, ... PLoS One 9 (6), e99440, 2014 | 46 | 2014 |
| Observed bromodomain flexibility reveals histone peptide-and small molecule ligand-compatible forms of ATAD2 G Poncet-Montange, Y Zhan, JP Bardenhagen, A Petrocchi, E Leo, X Shi, ... Biochemical Journal 466 (2), 337-346, 2015 | 42 | 2015 |
| Prion protein—antibody complexes characterized by chromatography-coupled small-angle X-ray scattering L Carter, SJ Kim, D Schneidman-Duhovny, J Stöhr, G Poncet-Montange, ... Biophysical journal 109 (4), 793-805, 2015 | 39 | 2015 |
| Screening and in situ synthesis using crystals of a NAD kinase lead to a potent antistaphylococcal compound M Gelin, G Poncet-Montange, L Assairi, L Morellato, V Huteau, L Dugué, ... Structure 20 (6), 1107-1117, 2012 | 35 | 2012 |
| A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets G Poncet-Montange, SJS Martin, OV Bogatova, SB Prusiner, BK Shoichet, ... Journal of Biological Chemistry 286 (31), 27718-27728, 2011 | 35 | 2011 |
| Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity A Ayrolles-Torro, T Imberdis, J Torrent, K Toupet, IV Baskakov, ... Journal of Neuroscience 31 (42), 14882-14892, 2011 | 25 | 2011 |
| Phosphorylation of threonine residues on Shc promotes ligand binding and mediates crosstalk between MAPK and Akt pathways in breast cancer cells KM Suen, CC Lin, C Seiler, R George, G Poncet-Montange, AB Biter, ... The International Journal of Biochemistry & Cell Biology 94, 89-97, 2018 | 14 | 2018 |
| Lack of dynamics in the MabA active site kills the enzyme activity: practical consequences for drug-design studies G Poncet-Montange, S Ducasse-Cabanot, A Quemard, G Labesse, ... Acta Crystallographica Section D: Biological Crystallography 63 (8), 923-925, 2007 | 14 | 2007 |
| Regulation of kinase activity by combined action of juxtamembrane and C-terminal regions of receptors CC Lin, L Wieteska, G Poncet-Montange, KM Suen, ST Arold, Z Ahmed, ... BioRxiv, 2020.10. 01.322123, 2020 | 2 | 2020 |
| Antibacterial compounds S Pochet, G Labesse, M Gelin, L Assairi, O Dussurget, ... US Patent 8,927,520, 2015 | 1 | 2015 |
| The combined action of the intracellular regions regulates FGFR2 kinase activity CC Lin, L Wieteska, G Poncet-Montange, KM Suen, ST Arold, Z Ahmed, ... Communications Biology 6 (1), 728, 2023 | | 2023 |
| The human orphan nuclear receptor tailless (TLX, NR2E1) is druggable R Fletterick, C Benod, R Villagomez, CS Filgueira, PK Hwang, ... | | 2014 |
| Antibacterial Diadenosine Compounds S Pochet, G Labesse, M Gelin, L Assairi, O Dussurget, ... | | 2014 |
| Novel antibacterial compounds S Pochet, G Labesse, M Gelin, L Assairi, O Dussurget, ... | | 2012 |
| Trapping Prions with Thienyl Pyrimidine Compounds A Ayrolles-Torro, T Imberdis, J Torrent, IV Baskakov, G Poncet-Montange, ... PRION 5, 75-76, 2011 | | 2011 |
| Dimerization of PrPSc by Thienyl Pyrimidine Compounds Trap Prion Infectivity A Ayrolles-Torro, K Toupet, J Torrent, I Baskakov, G Poncet-Montange, ... PRION 4 (3), 204-204, 2010 | | 2010 |
| Enzymatic mechanism of bacterial NAD kinases L Assairi, G Poncet-Montange, S Pochet, G Labesse FEBS JOURNAL 277, 267-267, 2010 | | 2010 |
| Études structurales et fonctionnelles de la NAD Kinase 1 de Listeria monocytogènes: vers une conception rationnelle de ligands utilisant une approche par fragment G Poncet-Montange Montpellier 1, 2007 | | 2007 |
